Precisely Hitting the Agressive Front of Cancer

c-Met receptor is expressed in 17+ cancer types and is associated with metastases, poor clinical outcomes and resistance to targeted therapies

 

EMP is exploiting a clinically proven proprietary c-Met binding peptide to seek and destroy cancer with radioactive isotopes